Specifically, the reduction of NF-κB activation by COX-2 inhibitors (e.g., SC-236) and PGE2 antagonists (e.g., BSP) is in line with previous work indicating the crucial role of COX-2 and PGE2 in controlling inflammation and immune responses during viral infections [52,53]. The gene discussed is NFKB1; the disease is viral infectious disease.